/PRNewswire/ - Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed.
New project started to jointly develop Artilysin(R)s as innovative novel treatment option for infected, chronic wounds such as diabetic foot infections, the most common complication of diabetes mellitusExpansion